



## NewsBREAK | Nov. 2

### CMS Issues Final Rule on Part B Immunosuppressive Drug Benefit

- The ***Medicare Program; Implementing Certain Provisions of the Consolidated Appropriations Act, 2021 and other Revisions to Medicare Enrollment and Eligibility Rules*** final rule implements certain provisions of the Consolidated Appropriations Act, 2021 (CAA) ([P.L. 116-260](#)) and is expected to be published in the Federal Register on Nov. 3, 2022.
- The rule is effective on Jan. 1, 2023, except for § 407.47(f) (Limitations on retroactive adjustments in the case of retroactive Medicare Part A entitlement) which is effective on Jan. 1, 2024.
- Extended Coverage of Immunosuppressive Drugs for Certain Kidney Transplant Patients - The CAA permits certain kidney transplant patients to receive a limited Part B benefit covering certain immunosuppressive drugs and provides limited eligibility under Part B for certain beneficiaries whose insurance benefits under Part A are ending. These individuals may be eligible for the new Part B immunosuppressive drug benefit ("Part B-ID"). The final rule provides greater detail on the limitations on eligibility for this benefit.
- The final rule also would simplify regulations related to Medicare enrollment forms.

See the final rule for a complete list of requirements.

---

### More on This Topic

- [Text of final rule](#)
- [CAA](#)

For questions, please reach out to [Tyler Thorne](#).

[Contact Us For Membership Info](#) | [Become a Member](#)

AMCP | 675 North Washington Street, Suite 220 | Alexandria, Virginia 22314  
Please [manage your emails here](#).

